Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.

Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y.

J Gastroenterol. 2018 Mar;53(3):438-448. doi: 10.1007/s00535-017-1372-8. Epub 2017 Jul 25.

PMID:
28744823
2.

Examination time as a quality indicator of screening upper gastrointestinal endoscopy for asymptomatic examinees.

Kawamura T, Wada H, Sakiyama N, Ueda Y, Shirakawa A, Okada Y, Sanada K, Nakase K, Mandai K, Suzuki A, Kamaguchi M, Morita A, Nishioji K, Tanaka K, Mochizuki N, Uno K, Yokota I, Kobayashi M, Yasuda K.

Dig Endosc. 2017 Jul;29(5):569-575. doi: 10.1111/den.12804. Epub 2017 Feb 10.

PMID:
28066945
3.

Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.

Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y.

World J Hepatol. 2015 Dec 8;7(28):2841-8. doi: 10.4254/wjh.v7.i28.2841.

4.

The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals.

Nishioji K, Mochizuki N, Kobayashi M, Kamaguchi M, Sumida Y, Nishimura T, Yamaguchi K, Kadotani H, Itoh Y.

PLoS One. 2015 Oct 20;10(10):e0140427. doi: 10.1371/journal.pone.0140427. eCollection 2015.

5.

Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012.

Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, Yamaguchi K, Itoh Y.

J Gastroenterol. 2015 Jan;50(1):95-108. doi: 10.1007/s00535-014-0948-9. Epub 2014 Mar 12.

PMID:
24619537
6.

[Severe advanced lower gingival carcinoma effectively reduced by chemoradiation with S-1--report of a case].

Ishibashi M, Masuda N, Noguchi K, Moridera K, Nishimura N, Takayama T, Nishioji K, Urade M, Kogo M.

Gan To Kagaku Ryoho. 2007 Nov;34(11):1837-9. Japanese.

PMID:
18030019
7.

The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.

Shindo M, Hamada K, Nishioji K, Muramatsu A, Oda Y, Okuno T.

J Gastroenterol. 2004;39(3):260-7.

PMID:
15065004
8.

Activated Kupffer cells play an important role in intra-hepatic Th1-associated necro-inflammation in Concanavalin A-induced hepatic injury in mice.

Morita A, Itoh Y, Toyama T, Fujii H, Nishioji K, Kirishima T, Makiyama A, Yamauchi N, Okanoue T.

Hepatol Res. 2003 Oct;27(2):143-150.

PMID:
14563429
9.

Time course profile and cell-type-specific production of monokine induced by interferon-gamma in Concanavalin A-induced hepatic injury in mice: comparative study with interferon-inducible protein-10.

Itoh Y, Morita A, Nishioji K, Fujii H, Nakamura H, Kirishima T, Toyama T, Yamauchi N, Nagao Y, Narumi S, Okanoue T.

Scand J Gastroenterol. 2001 Dec;36(12):1344-51.

PMID:
11761028
10.

Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels.

Itoh Y, Morita A, Nishioji K, Narumi S, Toyama T, Daimon Y, Nakamura H, Kirishima T, Okanoue T.

J Viral Hepat. 2001 Sep;8(5):341-8.

PMID:
11555191
11.

Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes.

Nishioji K, Okanoue T, Itoh Y, Narumi S, Sakamoto M, Nakamura H, Morita A, Kashima K.

Clin Exp Immunol. 2001 Feb;123(2):271-9.

12.

TNF-alpha is a potent inducer for IFN-inducible protein-10 in hepatocytes and unaffected by GM-CSF in vivo, in contrast to IL-1beta and IFN-gamma.

Narumi S, Yoneyama H, Inadera H, Nishioji K, Itoh Y, Okanoue T, Matsushima K.

Cytokine. 2000 Jul;12(7):1007-16.

PMID:
10880246
13.

Liver-infiltrating T lymphocytes are attracted selectively by IFN-inducible protein-10.

Tamaru M, Nishioji K, Kobayashi Y, Watanabe Y, Itoh Y, Okanoue T, Murai M, Matsushima K, Narumi S.

Cytokine. 2000 Apr;12(4):299-308.

PMID:
10805209
14.
15.

Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection.

Itoh Y, Okanoue T, Ohnishi N, Sakamoto M, Nishioji K, Nakagawa Y, Minami M, Murakami Y, Kashima K.

Am J Gastroenterol. 1999 May;94(5):1332-40.

PMID:
10235215
16.

Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor.

Itoh Y, Okanoue T, Ohnishi N, Nishioji K, Sakamoto S, Nagao Y, Nakamura H, Kirishima T, Kashima K.

Liver. 1999 Apr;19(2):97-103.

PMID:
10220738
17.
18.

Dynamics of hepatitis C viremia following interferon-alpha administration.

Yasui K, Okanoue T, Murakami Y, Itoh Y, Minami M, Sakamoto S, Sakamoto M, Nishioji K.

J Infect Dis. 1998 Jun;177(6):1475-9.

PMID:
9607822
19.

Intercellular adhesion molecule-1 and CD18 are involved in neutrophil adhesion and its cytotoxicity to cultured sinusoidal endothelial cells in rats.

Sakamoto S, Okanoue T, Itoh Y, Sakamoto K, Nishioji K, Nakagawa Y, Yoshida N, Yoshikawa T, Kashima K.

Hepatology. 1997 Sep;26(3):658-63.

PMID:
9303496
20.

Expression of IFN-inducible protein-10 in chronic hepatitis.

Narumi S, Tominaga Y, Tamaru M, Shimai S, Okumura H, Nishioji K, Itoh Y, Okanoue T.

J Immunol. 1997 Jun 1;158(11):5536-44.

PMID:
9164978
21.

The effects of prednisolone and interferons on serum macrophage colony stimulating factor concentrations in chronic hepatitis B.

Itoh Y, Okanoue T, Sakamoto S, Nishioji K, Kashima K.

J Hepatol. 1997 Feb;26(2):244-52.

PMID:
9059942
22.

Side effects of high-dose interferon therapy for chronic hepatitis C.

Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K.

J Hepatol. 1996 Sep;25(3):283-91.

PMID:
8895006
23.

Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon.

Itoh Y, Okanoue T, Sakamoto S, Nishioji K, Yasui K, Sakamoto M, Kashima K.

Dig Dis Sci. 1995 Nov;40(11):2423-30.

PMID:
7587825
24.

Serum autoantibody against interleukin-1 alpha is unrelated to the etiology or activity of liver disease but can be raised by interferon treatment.

Itoh Y, Okanoue T, Sakamoto S, Nishioji K, Kashima K, Ohmoto Y.

Am J Gastroenterol. 1995 May;90(5):777-82.

PMID:
7733087
25.

[A case of drug-induced hepatitis caused by Oriental herb-drug sai-rei-to].

Nishioji K, Itoh Y, Sakamoto Y, Tokita K, Mitsufuji S, Yokota S, Tsuji T, Okanoue T, Kashima K.

Nihon Shokakibyo Gakkai Zasshi. 1994 Oct;91(10):2016-20. Japanese. No abstract available.

PMID:
7967141

Supplemental Content

Loading ...
Support Center